Uses patented mammary biotechnology to cultivate functional human milk components from mammary cells in a scalable biomanufacturing process. This technology addresses the limitations of current infant nutrition by producing bioactive milk ingredients that support gut, immune, and brain health, aiming to integrate them into products like infant formula.
Funding
$24.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current infant formulas, while life-saving, lack many of the bioactive components found in human breast milk, which are crucial for infant development, immunological processes, and physiological functions. Existing production methods for replicating human milk components are limited in terms of what can be reproduced and often rely on animal-derived proteins.
Solution
BIOMILQ leverages mammary biotechnology to produce functional human milk components from mammary epithelial cells, bridging the gap between infant formula and breast milk. The company isolates mammary epithelial cells from donated breast milk to create a proprietary cell bank. These cells are then optimized to produce bio-authentic human milk components through a scalable biomanufacturing process. This technology aims to replicate the complex biosynthetic pathways of human milk, focusing on potent functional molecules that cannot be easily produced through other methods like microbial precision fermentation.
Target Audience
The primary target audience includes early-life nutrition and ingredient companies seeking to enhance infant formula with bio-authentic human milk components, as well as parents looking for alternatives that bring the nutritional profile of formula closer to breast milk.
Features
- Proprietary cell bank of human mammary epithelial cells isolated from donated breast milk
- Scalable biomanufacturing process for producing human milk components
- Production of bio-authentic human milk components with complex biosynthetic pathways
- Focus on potent functional molecules that cannot be easily produced through other methods
- Production of human osteopontin (OPN) with a more bio-authentic phosphorylation signature compared to bovine OPN
- Research and development of downstream-processing approaches for incorporating human milk components into infant formula